# ECLYPse: HCP commentary report

> 20 verified statements (12 from clinicians verified by NPI or staff page) from 7 commentary sources · 4 findings · updated Oct 29, 2026

## Report

- Trial: Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
- NCT ID: NCT06640166
- Registry: https://clinicaltrials.gov/study/NCT06640166
- Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Phase: Phase 2
- Status: Recruiting
- Indications: Colorectal cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: da6ed010b258737c4e5a9562823482a18159909d2e09f1cc3c53175a3349f05f

## Counts

- HCP commentary sources screened: 17
- Sources cited by verified statements: 7
- Verified statements: 20
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 12
- Findings: 4
- People found in screened sources: 14
- Voices cited: 13
- Cited voices identity-verified: 11

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ECLYPse asks whether adding FOLFIRI while continuing encorafenib/cetuximab after progression benefits patients with BRAF V600E–mutant metastatic colorectal cancer. Practice-impact judgments in the sources reviewed for this edition range from an X poster’s description of a reasonable option to a medical oncologist’s emphatic endorsement. A physician favors continuation over rechallenge, while an X poster raises a mechanistic question. The biological explanation remains open in the discussion.

## Open Medical Affairs question

What comparative evidence would justify a standard-of-care recommendation, and what explains the apparent benefit?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A concrete sequencing proposal attracts support, but standard-of-care adoption is contested
- F2. Practice-impact judgments range from a reasonable option to emphatic endorsement
- F3. Continuation is favored over rechallenge by one speaker, but the mechanism remains a question
- F4. The connected treatment discussion preserves a selective local-therapy option

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 5 | 5 | 1 | 4 | recorded | 2 |
| F2 | 7 | 7 | 6 | 5 | none recorded | 4 |
| F3 | 4 | 4 | 3 | 4 | none recorded | 2 |
| F4 | 4 | 4 | 1 | 4 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 0 | 1 | 0 | 0 | 5 | 4 | 1 post or article | yes |
| F2 | 6 | 0 | 0 | 0 | 1 | 7 | 1 | 5 posts and articles, 1 podcast or video | yes |
| F3 | 2 | 1 | 0 | 1 | 0 | 4 | 1 | 3 posts and articles | yes |
| F4 | 3 | 0 | 1 | 0 | 0 | 4 | 1 | 1 post or article | yes |

### Trial dimensions

- Primary endpoint: 6-month Progression Free Survival rate: F2 (3 shared claims)
- Secondary endpoints: F2 (4 shared claims), F3 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (4 shared claims), F3 (1 shared claims)
- The comparison: F1 (4 shared claims), F3 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F3. Continuation is favored over rechallenge by one speaker, but the mechanism remains a question

X-thread questions address biological mechanism and whether continued treatment beyond progression is analogous to another treatment strategy.

Source: X thread, 2026-10-24.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 20 | Paid |
| Trial aspects mapped | 9 | Free |
| Sources with links | 7 | Counts free |
| Speaker attribution for cited voices | 13 | Paid |

## Trial aspects

8 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: 6-month Progression Free Survival rate | discussed | 3 | 3 |
| Secondary endpoints | discussed | 4 | 4 |
| Population and setting | discussed | 6 | 6 |
| The comparison | discussed | 6 | 2 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 3 | 2 |
| Practice adoption and sequencing after first-line targeted therapy plus chemotherapy | discussed | 6 | 2 |
| Continuation versus rechallenge and the unresolved biological explanation | discussed | 4 | 3 |
| Conversion therapy and local treatment in selected oligometastatic disease | discussed | 4 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 15 | 6 |
| X videos | 1 | 1 |
| YouTube | 1 | 0 |

- Screened window: 2024-04-13 to 2026-10-24
- Cited window: 2026-10-10 to 2026-10-24
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
- Registry: NCT06640166 (https://clinicaltrials.gov/study/NCT06640166)
- Study IDs: 6070 · 2023-508615-24-00
- Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Collaborators: Pierre Fabre Pharma GmbH
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Recruiting
- Enrollment: 25 (estimated)
- Start: 2024-06-03 (actual)
- Primary completion: 2025-12-31 (estimated)
- Primary endpoint: 6-month Progression Free Survival rate (6 months after the enrollment of the last patient.)
- Intervention: encorafenib + cetuximab + FOLFIRI (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on continuing targeted therapy beyond progression with chemotherapy and the need for more translational evidence.
- Not yet captured in this edition: a view on continuing encorafenib plus cetuximab beyond progression with FOLFIRI and the need for more translational data.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This report reflects the sources reviewed for this edition, not all public discussion or the prevalence of views among HCPs. Reposts should not be counted as independent endorsements.
- One discussion could not be read, two potentially relevant passages were not fully assessed, and some additional comments could not be confidently attributed. Further qualifications or consequential views may therefore be absent.
- No exact-trial results publication or protocol was available, and no regulatory label for the precise combination was identified. The commentary cannot establish approved use or independently resolve comparative benefit.
- The reported treatment lines and six-month PFS percentages differ across sources and cannot be reconciled from the available statements.
- The proof-of-concept sample and endpoint-evaluable denominator are small, OS is described as immature or not reached, and the reviewed commentary provides no tolerability assessment. Favorable efficacy interpretations should not be read as settled comparative or safety conclusions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (20 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/eclypse-nct06640166
- Agents: POST https://www.erudio.com/api/orders with {"report": "eclypse-nct06640166", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=eclypse-06640166

## Cite

Erudio Health. ECLYPse (NCT06640166): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/eclypse-nct06640166

## Machine access

- JSON: https://www.erudio.com/reports/eclypse-nct06640166.json
- Markdown: https://www.erudio.com/reports/eclypse-nct06640166.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "eclypse-06640166"}`